Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment

被引:42
作者
Belloni, Daniela [1 ]
Heltai, Silvia [1 ]
Ponzoni, Maurilio [2 ,3 ]
Villa, Antonello [4 ]
Vergani, Barbara [4 ]
Pecciarini, Lorenza [2 ]
Marcatti, Magda [5 ]
Girlanda, Stefania [5 ]
Tonon, Giovanni [6 ]
Ciceri, Fabio [3 ,5 ]
Caligaris-Cappio, Federico [1 ,3 ,7 ]
Ferrarini, Marina [1 ]
Ferrero, Elisabetta [1 ]
机构
[1] IRCCS San Raffaele Sci Inst, Div Expt Oncol, Milan, Italy
[2] IRCCS San Raffaele Sci Inst, Pathol Unit, Milan, Italy
[3] Univ Vita Salute San Raffaele, Milan, Italy
[4] Univ Milano Bicocca, Consorzio MIA, Milan, Italy
[5] IRCCS San Raffaele Sci Inst, Hematol, Milan, Italy
[6] Ist Sci San Raffaele, Div Expt Oncol, Funct Genom Canc Unit, Milan, Italy
[7] AIRC, Milan, Italy
关键词
CANCER DEVELOPMENT; CELLS; RESISTANCE; TISSUE; BORTEZOMIB; AKT; PROLIFERATION; MECHANISMS; PROMOTES; THERAPY;
D O I
10.3324/haematol.2017.167486
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma develops primarily inside the bone marrow microenvironment, that confers pro-survival signals and drug resistance. 3D cultures that reproduce multiple myeloma-bone marrow interactions are needed to fully investigate multiple myeloma pathogenesis and response to drugs. To this purpose, we exploited the 3D Rotary Cell Culture System bioreactor technology for myeloma-bone marrow co-cultures in gelatin scaffolds. The model was validated with myeloma cell lines that, as assessed by histochemical and electron-microscopic analyses, engaged contacts with stromal cells and endothelial cells. Consistently, pro-survival signaling and also cell adhesion-mediated drug resistance were significantly higher in 3D than in 2D parallel co-cultures. The contribution of the VLA-4/VCAM1 pathway to resistance to bortezomib was modeled by the use of VCAM1 transfectants. Soluble factor-mediated drug resistance could be also demonstrated in both 2D and 3D co-cultures. The system was then successfully applied to co-cultures of primary myeloma cells-primary myeloma bone marrow stromal cells from patients and endothelial cells, allowing the development of functional myeloma-stroma interactions and MM cell long-term survival. Significantly, genomic analysis performed in a high-risk myeloma patient demonstrated that culture in bioreactor paralleled the expansion of the clone that ultimately dominated in vivo. Finally, the impact of bortezomib on myeloma cells and on specialized functions of the microenvironment could be evaluated. Our findings indicate that 3D dynamic culture of reconstructed human multiple myeloma microenvironments in bioreactor may represent a useful platform for drug testing and for studying tumor-stroma molecular interactions.
引用
收藏
页码:707 / 716
页数:10
相关论文
共 44 条
  • [1] The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration
    Belloni, Daniela
    Scabini, Silvia
    Foglieni, Chiara
    Veschini, Lorenzo
    Giazzon, Alessio
    Colombo, Barbara
    Fulgenzi, Alessandro
    Helle, Karen B.
    Ferrero, Maria Elena
    Corti, Angelo
    Ferrero, Elisabetta
    [J]. FASEB JOURNAL, 2007, 21 (12) : 3052 - 3062
  • [2] Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis
    Belloni, Daniela
    Marcatti, Magda
    Ponzoni, Maurilio
    Ciceri, Fabio
    Veschini, Lorenzo
    Corti, Angelo
    Cappio, Federico Caligaris
    Ferrarini, Marina
    Ferrero, Elisabetta
    [J]. EXPERIMENTAL CELL RESEARCH, 2015, 330 (01) : 1 - 12
  • [3] Bortezomib induces autophagic death in proliferating human endothelial cells
    Belloni, Daniela
    Veschini, Lorenzo
    Foglieni, Chiara
    Dell'Antonio, Giacomo
    Caligaris-Cappio, Federico
    Ferrarini, Marina
    Ferrero, Elisabetta
    [J]. EXPERIMENTAL CELL RESEARCH, 2010, 316 (06) : 1010 - 1018
  • [4] Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
    Bolli, Niccolo
    Avet-Loiseau, Herve
    Wedge, David C.
    Van Loo, Peter
    Alexandrov, Ludmil B.
    Martincorena, Inigo
    Dawson, Kevin J.
    Iorio, Francesco
    Nik-Zainal, Serena
    Bignell, Graham R.
    Hinton, Jonathan W.
    Li, Yilong
    Tubio, Jose M. C.
    McLaren, Stuart
    Meara, Sarah O'
    Butler, Adam P.
    Teague, Jon W.
    Mudie, Laura
    Anderson, Elizabeth
    Rashid, Naim
    Tai, Yu-Tzu
    Shammas, Masood A.
    Sperling, Adam S.
    Fulciniti, Mariateresa
    Richardson, Paul G.
    Parmigiani, Giovanni
    Magrangeas, Florence
    Minvielle, Stephane
    Moreau, Philippe
    Attal, Michel
    Facon, Thierry
    Futreal, P. Andrew
    Anderson, Kenneth C.
    Campbell, Peter J.
    Munshi, Nikhil C.
    [J]. NATURE COMMUNICATIONS, 2014, 5
  • [5] The microenvironment in mature B-cell malignancies: a target for new treatment strategies
    Burger, Jan A.
    Ghia, Paolo
    Rosenwald, Andreas
    Caligaris-Cappio, Federico
    [J]. BLOOD, 2009, 114 (16) : 3367 - 3375
  • [6] A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells
    Calimeri, T.
    Battista, E.
    Conforti, F.
    Neri, P.
    Di Martino, M. T.
    Rossi, M.
    Foresta, U.
    Piro, E.
    Ferrara, F.
    Amorosi, A.
    Bahlis, N.
    Anderson, K. C.
    Munshi, N.
    Tagliaferri, P.
    Causa, F.
    Tassone, P.
    [J]. LEUKEMIA, 2011, 25 (04) : 707 - 711
  • [7] Osteogenic differentiation of mesenchymal stromal cells in two-dimensional and three-dimensional cultures without animal serum
    Castren, Eeva
    Sillat, Tarvo
    Oja, Sofia
    Noro, Ariel
    Laitinen, Anita
    Konttinen, Yrjo T.
    Lehenkari, Petri
    Hukkanen, Mika
    Korhonen, Matti
    [J]. STEM CELL RESEARCH & THERAPY, 2015, 6
  • [8] Structural analysis of rat bone explants kept in vitro in simulated microgravity conditions
    Cosmi, F.
    Steimberg, N.
    Dreossi, D.
    Mazzoleni, G.
    [J]. JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS, 2009, 2 (02) : 164 - 172
  • [9] 3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?
    de la Puente, Pilar
    Azab, Abdel Kareem
    [J]. FUTURE ONCOLOGY, 2016, 12 (13) : 1545 - 1547
  • [10] Ferrarini M, 2013, MULTIPLE MYELOMAA QU, DOI [10.5772/54312, DOI 10.5772/54312]